Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Wednesday announced progress in the design and planning of its upcoming Phase 3 ...

NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its ...

Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...

For many patients with schizophrenia, other psychiatric illnesses, or diseases such as hypertension and asthma, it can be ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

Arizona health officials reported the state’s first measles cases of the year, four Navajo County individuals who were not ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Billionaire investor Steve Cohen invested over $100 million in two biopharma stocks, one of which has rallied over 90% in the ...

A phase II study has revealed that combining the JAK inhibitor tofacitinib (Xeljanz) with the investigational drug ...

The VIASKIN peanut patch (VP250) is safe and effective for children aged 1 to 3 years who have peanut allergy, with and without atopic comorbidities.